We believe that Lifor™ is the preservation solution of the future. It was invented with a passion for improving organ and tissue

Through the development of Lifor™, the concept in the forefront of our approach has always been to improve the science and safety of the tissue and grafts. The initial goal was to improve on the other preservation alternatives by providing better nutrients for cell growth and overall improved preservation by nullifying the need to be flushed from the tissue or organ. This original solution was formulated to contain less salts and sugar so not to cause any adverse side effects such as heart or kidney failure when grafting organs. Lifor™ significantly mitigated both warm and cold renal reperfusion injury and affords greater protection from apoptosis. Over time, Lifor™ has gone through significant testing by leaders in the field of Sperm, Tissue, and Organ Preservation. That testing led to the creation of the second version of Lifor™ where the goal was to eliminate the dangerous agents that cause viral contamination and to tissue by freezing or cryopreserving for short term preservation

The second version of Lifor™ became a true synthetic and removed all human and animal proteins and growth factors to eliminate all harmful and potentially dangerous allergenic and viral causing substances that were used in the name of saving organs.

That brings us to the most recent patent-pending version of the solution currently in production. This product now promotes metabolism over a wide range of temperature gradients including room temperature and prevents organ and tissue damage on a cellular level. It also has the capability to reverse harvesting damage. We continue to push the advancement of Lifor™ and the future is yet to be seen. Testing continues in the fields of Cryopreservation, Flow Cytometry, and Long-Term Tissue Transport and we continue to push the research into new therapeutic areas and applications.

The Evolution Of Lifor

  • 2001

    Lifeblood Medical Incfounded

  • 2003

    Lifor Developed Patent Filed

  • 2004

    First kidney study performed at UC Davis

  • 2005

    Scaled batch size from 1L to 100L

  • 2006

    Congressional earmark grant approved

  • 2007

    Performed baboon kidney study with United States Naval Group at Walter Reed Army Hospital

  • 2008

    Performed limb preservation study on swine

  • 2009

    Changed Liforto all protein / sierum free

  • 2013

    Began fluid replacement investigation

  • 2014

    Compared Lifor to Belzer's in a non human primate study

  • 2016

    Fluid replacement First proof of principle study completed

  • 2018

    Lifor Improved New patent filed

Lifor Properties

Key to Lifor® Technology is effectiveness at the Cellular Level

Regardless of the composition of the cells

Regardless of the application

Enhances tissue oxygenation using robust nano-carrier Liposome Complex

Works at varying temperatures

Lifor vs. the Alternatives

No animal/human proteins or serum

Room preservation up to 72 hours for organs, biopsy’s and tissue

No flushing required when preserving with Lifor

Enhancement of oxygen carry capability

Room temperature preservation for heart, liver & kidney

Room temperature preservation of organs, biopsy’s and tissue

Application of Lifor

In order to aid in diagnostics, cell, tissue and organ samples are taken from patients for use in testing – which is needed to diagnose health disorders such as cancer and other diseases. Currently, fixative agents are used to preserve samples until testing can be done, as a key problem in diagnostics is that protein molecules immediately undergo degredation immediately when removed from the body. 

While the fixative agents are meant to aid in Transportation to testing, they can also affect the sample quality (e.g. making tissue antigens inaccessible to the primary antibodies used in immunocytochemistry – antigen masking) and this has to be taken into consideration in any test analysis. Formaldehyde, which is used in the current fixative agent, also induces DNA degradation and the degeneration of tissue nucleic acids and artificial mutations. 

Our Product

Our next-generation solutions under development will hold cells, tissues, and organs for far longer than existing technologies, all while minimizing damage to cellular structures and ensuring improved levels of test accuracy. It does not need to be used in conjunction with a fixative agent such as formaldehyde which affects sample quality.